AR107027A1 - COMPLEMENTARY ACTIVITY MODULATORS - Google Patents

COMPLEMENTARY ACTIVITY MODULATORS

Info

Publication number
AR107027A1
AR107027A1 ARP160103773A ARP160103773A AR107027A1 AR 107027 A1 AR107027 A1 AR 107027A1 AR P160103773 A ARP160103773 A AR P160103773A AR P160103773 A ARP160103773 A AR P160103773A AR 107027 A1 AR107027 A1 AR 107027A1
Authority
AR
Argentina
Prior art keywords
modulators
complementary activity
concentration
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
ARP160103773A
Other languages
Spanish (es)
Inventor
A Treco Douglas
Tobe Sylvia
Ricardo Alonso
Victoria Parker Grace
Denise Arata Michelle
James Demarco Steven
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of AR107027A1 publication Critical patent/AR107027A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Moduladores polipeptídicos de actividad complementaria que incluyen moduladores polipeptídicos cíclicos de actividad complementaria. Métodos para utilizar dichos moduladores como agentes terapéuticos. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende R5000 y un excipiente farmacéuticamente aceptable, donde el excipiente farmacéuticamente aceptable comprende cloruro de sodio en una concentración de entre aproximadamente 25 mM y aproximadamente 100 mM y fosfato de sodio en una concentración de entre aproximadamente 10 mM y aproximadamente 100 mM. Reivindicación 7: Un método para inhibir la hemólisis en un sujeto, caracterizado porque comprende administrar una composición farmacéutica de cualquiera de las reivindicaciones 1 - 6.Complementary activity polypeptide modulators that include complementary cyclic polypeptide modulators. Methods for using such modulators as therapeutic agents. Claim 1: A pharmaceutical composition characterized in that it comprises R5000 and a pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient comprises sodium chloride in a concentration of between about 25 mM and about 100 mM and sodium phosphate in a concentration of between about 10 mM and approximately 100 mM. Claim 7: A method of inhibiting hemolysis in a subject, characterized in that it comprises administering a pharmaceutical composition of any one of claims 1-6.

ARP160103773A 2015-12-16 2016-12-07 COMPLEMENTARY ACTIVITY MODULATORS AR107027A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562268360P 2015-12-16 2015-12-16

Publications (1)

Publication Number Publication Date
AR107027A1 true AR107027A1 (en) 2018-03-14

Family

ID=61768583

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160103773A AR107027A1 (en) 2015-12-16 2016-12-07 COMPLEMENTARY ACTIVITY MODULATORS
ARP210100437A AR121381A2 (en) 2015-12-16 2021-02-19 PHARMACEUTICAL COMPOSITION INCLUDING MODULATORS OF COMPLEMENTARY ACTIVITY AND AUTOINJECTOR DEVICE

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210100437A AR121381A2 (en) 2015-12-16 2021-02-19 PHARMACEUTICAL COMPOSITION INCLUDING MODULATORS OF COMPLEMENTARY ACTIVITY AND AUTOINJECTOR DEVICE

Country Status (1)

Country Link
AR (2) AR107027A1 (en)

Also Published As

Publication number Publication date
AR121381A2 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
DOP2017000271A (en) PATIENT CONDITIONING METHODS FOR T-LYMPHOCYT TREATMENT
DOP2017000272A (en) METHODS OF DIAGNOSIS FOR TREATMENT WITH LYMPHOCYTES T
CL2015003442A1 (en) Heterocyclic derivatives
AR107014A1 (en) PHARMACEUTICAL FORMULATION WATER
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
BR112015006828A8 (en) compound, or a pharmaceutically acceptable salt thereof; pharmaceutical composition; use of the compound; and method for modulating the activity of an ire1 protein
MA38399A1 (en) Formulation in tablet form, useful for treating acute heart failure and chronic heart failure
MY188139A (en) Sodium channel modulators for the treatment of pain
AR105712A1 (en) QUICK ACTION INSULIN COMPOSITIONS
MX2018013973A (en) Methods of treating behavioral syndromes using pipradrol.
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
BR112018015367A2 (en) nanofiber oromucosal carriers for therapeutic treatment
CL2015002835A1 (en) New pyridine derivatives
MX2021002321A (en) Novel methods.
EA201501054A1 (en) TREATMENT OF MYOPATHIES AND NEURODEGENERATIVE DISEASES ASSOCIATED WITH THE PROTECTION OF PROTEINS BY PARENTAL INTRODUCTION OF TRAGOSE
AR111374A1 (en) USE OF LIK066 IN PATIENTS WITH HEART FAILURE
UY34896A (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN
EA201692402A1 (en) MEDICAL FORMS FOR LOCAL APPLICATION AND THEIR USE
CR20140075A (en) THERAPEUTIC METHODS
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
CL2016002318A1 (en) Pharmaceutical composition in the form of a solution comprising a liquid carrier comprising water and between 20% and 95% of one or more alcohols and sildenafil citrate dissolved in said liquid carrier at a concentration of between 7 and 125 mg / ml; methods to obtain it; oral dosage form; oral dosage form; kits
EA201792314A1 (en) PHARMACEUTICAL COMBINATION OF EVEROLIMUS AND DACTOLYSIB
BR112018068960A2 (en) enalapril formulations
EA201891319A1 (en) COMPOUNDS OF ALKYDYDYDROCHINOLINSULPHONAMIDE